Capital Impact Advisors LLC Buys 35,550 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Share on StockTwits

Capital Impact Advisors LLC boosted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 30.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 152,989 shares of the biotechnology company’s stock after acquiring an additional 35,550 shares during the period. Capital Impact Advisors LLC owned 0.13% of Corcept Therapeutics worth $2,101,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of CORT. Asset Management One Co. Ltd. acquired a new position in Corcept Therapeutics during the 1st quarter worth approximately $150,000. Stifel Financial Corp acquired a new stake in shares of Corcept Therapeutics in the 1st quarter worth approximately $182,000. Fox Run Management L.L.C. acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter worth approximately $211,000. Engineers Gate Manager LP acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter worth approximately $213,000. Finally, Stevens Capital Management LP acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter worth approximately $214,000. Hedge funds and other institutional investors own 75.20% of the company’s stock.

CORT stock traded down $0.37 on Friday, reaching $13.01. The company had a trading volume of 1,231,630 shares, compared to its average volume of 1,269,341. Corcept Therapeutics Incorporated has a 1 year low of $11.21 and a 1 year high of $25.96. The firm has a market cap of $1.60 billion, a P/E ratio of 29.57 and a beta of 1.80.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, November 1st. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). Corcept Therapeutics had a net margin of 63.79% and a return on equity of 32.96%. The company had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $67.42 million. During the same period in the previous year, the company posted $0.10 EPS. Corcept Therapeutics’s quarterly revenue was up 50.7% compared to the same quarter last year. On average, analysts anticipate that Corcept Therapeutics Incorporated will post 0.6 EPS for the current year.

A number of research firms recently weighed in on CORT. ValuEngine cut Corcept Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, August 13th. B. Riley lowered their price target on Corcept Therapeutics from $30.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, August 13th. BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, July 14th. Cantor Fitzgerald restated a “hold” rating and issued a $17.00 price target on shares of Corcept Therapeutics in a report on Friday, November 2nd. Finally, Stifel Nicolaus restated a “hold” rating and issued a $11.00 price target (down previously from $20.00) on shares of Corcept Therapeutics in a report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $21.83.

In other news, Director G Leonard Baker, Jr. bought 35,681 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The shares were acquired at an average cost of $12.92 per share, with a total value of $460,998.52. Following the transaction, the director now owns 876,838 shares of the company’s stock, valued at approximately $11,328,746.96. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Robert S. Fishman sold 8,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $13.74, for a total value of $109,920.00. Following the completion of the transaction, the insider now directly owns 8,000 shares in the company, valued at $109,920. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 321,159 shares of company stock worth $4,025,880 and sold 24,000 shares worth $332,000. 15.00% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://baseballnewssource.com/2018/11/10/capital-impact-advisors-llc-acquires-35550-shares-of-corcept-therapeutics-incorporated-cort/2847475.html.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Featured Story: Reverse Stock Split

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.